GeoVax Labs reported progress in its Mpox, COVID-19, and oncology programs during Q3 2025, driven by clinical advancements and strategic collaborations. The company is focusing on accelerating development and regulatory readiness for its GEO-MVA vaccine amidst a global Mpox emergency and expanding its Gedeptin® oncology program.
GEO-MVA development accelerated due to the global Mpox emergency and favorable scientific advice from the EMA supporting a streamlined regulatory pathway.
positiveGEO-CM04S1 COVID-19 vaccine demonstrated robust T-cell and cross-variant antibody responses in immunocompromised patients, exceeding standard-of-care mRNA vaccines in CLL patients.
positiveGedeptin® oncology program is expanding into new solid tumor indications, including a planned Phase 2 trial for head and neck cancer and preclinical studies in breast and cutaneous cancers.
positiveCompany's U.S.-based manufacturing process aligns with national policy priorities for onshoring and pandemic preparedness.
neutralRevenue from government contracts significantly decreased to $0 in Q3 2025 from $2.79M in Q3 2024, following BARDA's termination of the contract for convenience.
negativeNet loss increased to $6.32M in Q3 2025 from $5.82M in Q3 2024, with a year-to-date net loss of $17.05M compared to $16.73M in the prior year.
negativeLoss per common share widened to $0.31 in Q3 2025 from $0.91 in Q3 2024, and year-to-date loss per share was $0.97 compared to $4.52 in the prior year.
negativeCash and cash equivalents decreased to $5.01M at September 30, 2025, from $5.51M at December 31, 2024.
attentionResearch and development expenses decreased by 32% YoY in Q3 2025, primarily due to discontinued costs from the terminated BARDA contract, indicating a potential slowdown in R&D investment.
attentionMargin metrics will be available once backend extracts data from insights_json
GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs.
Our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform, positioned to accelerate regulatory readiness and commercial entry.
The robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.